Drug
Vosoritide clinical trials
Also written BMN 111.
- studies test it
- 17
- open now
- 4
- in phase 3
- 4
- first study started
- 2012
Keep track of what changes. Save the vosoritide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
Studies by the year they started
17 studies that test it; most in 2024 (4)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2014 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 11
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 3
BioMarin Pharmaceutical (14) · Andrew Dauber (1) · University of California, San Francisco (1) · Roopa Kanakatti Shankar, MBBS, MS (1)
Studies
Open first, then newest update. How each study uses vosoritide is read from its arms, and is right about nine times in ten.
Testing it · 17
- Long-Term Extension Study of Vosoritide to Treat Children With HypochondroplasiaEnrolling by invitationPhase 3BioMarin PharmaceuticalNCT07073014Written as Vosoritide
- A Phase 2 Study of Vosoritide in Children With Idiopathic Short StatureRecruitingPhase 2BioMarin PharmaceuticalNCT06382155Written as Vosoritide Injection
- A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 MonthsRecruitingPhase 2BioMarin PharmaceuticalNCT07126262Written as Vosoritide
- Vosoritide for Short Stature in Turner SyndromeRecruitingPhase 2Roopa Kanakatti Shankar, MBBS, MSNCT05849389Written as Vosoritide
- A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone TreatmentActive, not recruitingPhase 2BioMarin PharmaceuticalNCT06668805Written as Vosoritide Injection
- Vosoritide for Selected Genetic Causes of Short StatureActive, not recruitingPhase 2Andrew DauberNCT04219007Written as Vosoritide
- A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With AchondroplasiaActive, not recruitingPhase 2BioMarin PharmaceuticalNCT04554940Written as vosoritide
- An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With AchondroplasiaActive, not recruitingPhase 3BioMarin PharmaceuticalNCT03424018Written as BMN 111
- An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With AchondroplasiaActive, not recruitingPhase 2BioMarin PharmaceuticalNCT03989947Written as Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
- A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)Active, not recruitingPhase 2BioMarin PharmaceuticalNCT02724228Written as BMN 111
- Safety and Efficacy of Voxzogo for Growth Deficits in MPS IVA and VIActive, not recruitingPhase 1/2University of California, San FranciscoNCT05845749Written as Vosoritide Injection [Voxzogo]
- Interventional Study of Vosoritide for the Treatment of Children With HypochondroplasiaActive, not recruitingPhase 3BioMarin PharmaceuticalNCT06455059Written as Vosoritide
- A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With AchondroplasiaCompletedPhase 2BioMarin PharmaceuticalNCT03583697Written as BMN 111
- Bioequivalence Study to Compare Two Injection Devices for BMN 111 in Healthy ParticipantsTerminatedPhase 1BioMarin PharmaceuticalNCT05813314Written as BMN 111 administration via Injector Pen
- A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With AchondroplasiaCompletedPhase 3BioMarin PharmaceuticalNCT03197766Written as BMN 111
- A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With AchondroplasiaCompletedPhase 2BioMarin PharmaceuticalNCT02055157Written as BMN 111
- A Study to Evaluate Safety and Tolerability of BMN 111 Administered to Healthy Adult VolunteersCompletedPhase 1BioMarin PharmaceuticalNCT01590446Written as BMN 111
As the comparator · 1 — what is tested is compared with vosoritide
Codes
What other systems call vosoritide · ClinicalTrials.gg INT001131
- MeSH (NLM) C000632572vosoritideConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 7SE5582Q2PVOSORITIDEConfirmed FDA, NLM
- RxNorm 2586354One source FDA
- NCI Thesaurus C152918VosoritideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000632572 | vosoritide | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 7SE5582Q2P | VOSORITIDE | Confirmed FDA, NLM |
| RxNorm | 2586354 | — | One source FDA |
| NCI Thesaurus | C152918 | Vosoritide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.